Company news
Lixte Biotechnology Holdings, Inc. news in 2021
Lixte Biotechnology Holdings, Inc.'s news releases, calls and decks from 2021, newest first.
Lixte Biotechnology Holdings, Inc. announces that enrollment has resumed in National Cancer Institute’s trial to determine ability of Lixte compound LB-100 to enter recurrent, malignant brain tumors
November 21, 2021
Lixte Biotechnology Announces Collaboration with Netherlands Cancer Institute (Amsterdam) and Oncode Institute (Utrecht) to Identify the Most Promising Drug Combinations for its Lead Clinical Compound, LB-100, for Cancer Treatment
October 12, 2021
Lixte Biotechnology’s LB-100 Shown in Animal Models to Significantly Reduce Behavioral Sensitization, an Important Feature of Methamphetamine Addiction
August 16, 2021
Lixte Biotechnology’s LB-100 elicits anti- tumor activity in small lung cancer models by unique mechanisms in an important pre-clinical study
August 2, 2021
Lixte Biotechnology and City of Hope Enroll First Patient in Phase 1b Trial of Lead Compound LB-100 for Treatment of Small Cell Lung Cancer
June 1, 2021
Lixte Biotechnology Holdings, Inc. announces the appointment of Regina Brown to its board of directors
May 11, 2021
Lixte Biotechnology Holdings, Inc. Announces the Appointment of Gil N Schwartzberg to its Board of Directors
April 12, 2021
Lixte Biotechnology to Showcase Its Anti-Cancer Therapy Enhancer LB-100 at the Virtual 33rd Annual ROTH Capital Conference
March 2, 2021
Lixte Biotechnology Announces the Closing of $4.19 Million Registered Direct Offering
March 1, 2021
Lixte Biotechnology Announces $4.19 Million Registered Direct Offering
February 28, 2021
Lixte Biotechnology to Present Its Anti-Cancer Therapy Enhancer LB-100 at the Virtual H.C. Wainwright Global Life Sciences Conference
February 23, 2021
Lixte Biotechnology and City of Hope to Initiate Phase 1b Clinical Trial of Lixte’s Lead Compound LB-100 to Treat Small Cell Lung Cancer
January 18, 2021